实用老年医学 ›› 2010, Vol. 24 ›› Issue (1): 48-.

• 论著 • 上一篇    下一篇

氟伐他汀治疗轻、中度阿尔茨海默病的临床对照观察

  

  • 出版日期:2010-02-20 发布日期:2010-03-26

Clinical controlled observation in mild and moderate  Alzheimers disease treated by fluvastatin

  • Online:2010-02-20 Published:2010-03-26

摘要:

目的观察氟伐他汀对轻、中度阿尔茨海默病(AD)病人调脂疗效和对痴呆进展的影响。方法选择120例轻、中度AD病人随机分为研究组和对照组。对照组给予常规治疗,研究组在相同基础上每晚加服氟伐他汀40 mg。比较2组治疗前及治疗后4周、12周的血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDLC)、高密度脂蛋白胆固醇(HDLC)及简易智能状态量表(MMSE)、临床痴呆程度量表(CDR)、 老年痴呆患者生活质量量表(QOL)和日常生活活动能力量表(ADL)分数等指标,以MMSE、CDR、QOL 和ADL 为主要评价指标。结果研究组TC、TG、LDLC、HDLC水平及MMSE、CDR、ADL、QOL 分数的改善优于对照组,差别有统计学意义(P<005)。结论氟伐他汀在降血脂的同时可能延缓轻、中度AD的进展。

Abstract:

ObjectiveTo observe the curative effects of fluvastatin in treatment of mild and moderate Alzheimers disease.Methods120 patients with mild and moderate Alzheimers disease were randomly divided into the control group and the study  group. The control group received conventional therapy,while the study group was administrated orally with 40 mg of fluvastatin every evening additionally. The levels of TC,TG,LDLC,HDLC as well as the scores of MMSE,CDR and ADL were compared between the two groups at week 4 and week 12 after treatment, respectively.ResultsThe improvements of TC,TG,LDLC,HDLC and the scores of MMSE,CDR,QOL and ADL were significantly greater in the study group than those in the control group (P<005).ConclusionsFluvastatin can postpone the progress of mild and moderate Alzheimers disease, as well as lowering serum lipids.